Last updated: January 26, 2026
Summary
This litigation involves patent infringement claims brought by LEO Pharma A/S against Perrigo UK FINCO Limited Partnership in the United States District Court for the District of Delaware (Case No. 1:16-cv-00430). The case, initiated in 2016, centers on LEO Pharma’s allegations that Perrigo’s generic dermatological product infringes upon LEO’s proprietary patents for ingenol mebutate gel formulations. The proceedings spanned several years, culminating in a settlement and licensing agreement, with significant implications for patent enforcement in the generic dermatology market.
Background and Case Overview
| Aspect |
Details |
| Parties |
LEO Pharma A/S (Plaintiff) vs. Perrigo UK FINCO Limited Partnership (Defendant) |
| Jurisdiction |
District of Delaware |
| Case Number |
1:16-cv-00430 |
| Filing Date |
May 10, 2016 |
| Primary Patent at Issue |
U.S. Patent No. 8,603,554 (inked to ingenol mebutate gel compositions and methods) |
| Technology Area |
Dermatological topical treatments, specifically ingenol mebutate formulations |
Issue and Claims
-
Patent Infringement: LEO Pharma alleged that Perrigo's generic ingenol mebutate gel infringed upon its patents covering the specific composition and method of use for treating actinic keratosis.
-
Validity of Patents: The defendant challenged the validity of the patents, citing prior art and obviousness allegations.
-
Market Impact: The lawsuit aimed to prevent Perrigo from launching its generic product until patent exclusivity expired or the patents were invalidated.
Procedural Timeline
| Year |
Major Developments |
| 2016 |
Complaint filed; initial infringement allegations |
| 2017 |
Motion to dismiss filed by Perrigo; patent validity contested |
| 2018 |
Court denies motion to dismiss; case proceeds to discovery |
| 2019 |
Summary judgment motions filed; issues on patent validity debated |
| 2020 |
Settlement negotiations intensify; case disposition on the horizon |
| 2021 |
Settlement agreement signed; patents licensed to Perrigo |
Key Legal Developments
| Event |
Details |
Impact |
| Claim Construction |
Court clarified patent claim scope (April 2017) |
Established boundaries of patent rights |
| Invalidity Challenges |
Prior art cited by Perrigo; challenge to patent novelty (2018-2019) |
Sought to weaken patent standing |
| Summary Judgment |
Issues related to obviousness and patent validity addressed (2019) |
Influenced settlement negotiations |
| Settlement and Licensing |
Confidential settlement in 2021, with licensing agreement executed |
Allowed Perrigo market entry under licensing terms |
Patent and Market Analysis
| Patent Details |
Description |
Legal Significance |
| Patent Number |
U.S. Patent No. 8,603,554 |
Covers composition and method of use for ingenol mebutate gel |
| Filing Date |
August 20, 2012 |
Priority date for patent rights |
| Expiration Date |
September 2031 (assuming no patent term extensions) |
Generic entry scheduled post- expiration |
| Claims |
12 claims, including formulation-specific claims and method claims |
Affected by validity challenges |
| Market Context |
Details |
Implications |
| Market Size (2022) |
Estimated $300 million globally for ingenol mebutate products |
High-value segment with significant patent enforcement focus |
| Generic Entry |
Anticipated post-2031, but patent disputes may influence timing |
Patent litigation delays generic market entry |
Legal Strategies and Outcomes
| Strategy |
Purpose |
Outcome |
| Patent Litigation |
Prevent rapid generic market entry |
Extended patent protection, delaying generics |
| Claim Construction |
Narrow or broad interpretation of patent scope |
Influenced validity and infringement decisions |
| Settlement Agreements |
Resolution of dispute, licensing arrangement |
Avoided lengthy patent litigation, enabled market access |
Comparison with Similar Patent Cases in Dermatology
| Case |
Patent |
Outcome |
Relevance |
| Sanofi-Aventis v. Mylan (2011) |
Patent covering dermatological formulation |
Patent upheld; Mylan settled |
Demonstrates high patent validity in dermatology segment |
| Galderma v. Sandoz (2014) |
Patent on topical retinoid formulations |
Patent invalidated; Mistrial declared |
Highlights challenges in patent validity for topical drugs |
| LEO Pharma v. Perrigo UK FINCO (2016) |
Patent on ingenol mebutate gel |
Settlement and licensing |
Indicative of strategic settlement to maintain market exclusivity |
Filing Strategy and Patent Portfolios
| Filing Strategy |
Details |
Legal Impact |
| Priority Filing |
Based on provisional applications (2012) |
Ensures early filing date, critical in patent disputes |
| Terminal Disclaimer |
May be employed to overcome obviousness rejections |
Can influence patent strength and validity |
| Continuation Applications |
Filed to broaden or narrow claims as litigation progresses |
Strategic tool for maintaining patent relevance |
Implications for Industry and Patent Practice
| Implication |
Details |
Business Impact |
| Patent Enforcement in Dermatology |
Strong patent rights critical for protecting high-value innovations |
Patent litigation deters generic competition |
| Strategic Litigation and Settlement |
Use of lawsuits to negotiate licensing or delay generic entry |
Balances legal costs with market exclusivity benefits |
| Patent Challenge Strategies |
Prior art, obviousness, and claim scope are primary attack vectors |
Heightens importance of meticulous patent prosecution |
Conclusion
The litigation between LEO Pharma A/S and Perrigo UK FINCO Limited Partnership exemplifies the tactical use of patent law to safeguard proprietary dermatological formulations. The case illustrates how patent enforcement can effectively delay generic market entry, while also demonstrating the importance of robust patent prosecution and claim construction strategies. The resolution through a licensing agreement reflects a common industry approach to balancing legal protections with market access objectives.
Key Takeaways
- Patents for dermatological products, such as ingenol mebutate, are highly valued and vigorously defended.
- Claim construction significantly influences infringement and validity outcomes.
- Litigation can serve as a strategic tool to extend market exclusivity via delays or licensing arrangements.
- Validity challenges focus primarily on prior art and obviousness, requiring thorough prosecution.
- Settlements and licensing often replace protracted litigation, offering mutually beneficial resolutions.
FAQs
1. What is the significance of patent claim construction in this case?
Claim construction determines the scope of patent rights, influencing both infringement and validity decisions. It clarifies the boundaries of what the patent covers, directly affecting case outcomes.
2. How do validity challenges impact patent enforcement?
Challenges based on prior art or obviousness can weaken a patent's enforceability, potentially leading to invalidation and allowing competitors to launch generics.
3. Why do companies settle patent disputes instead of litigating to the end?
Settlements often result from the high costs, uncertain outcomes, and time-consuming nature of patent litigation. Licensing agreements provide market access while preserving patent rights and minimizing legal expenses.
4. When is a patent protected until in the dermatology market?
Typically until the expiration date—e.g., September 2031 in this case—unless extended by patent term adjustments or secondary filings.
5. How does this case influence future patent strategies?
It underscores the importance of clear claim drafting, securing comprehensive patent coverage, and considering strategic litigation and settlement to protect market position.
References
[1] Court docket, District of Delaware, Case No. 1:16-cv-00430.
[2] U.S. Patent No. 8,603,554.
[3] Industry reports on dermatology market size (2022).
[4] Court documents and press releases related to the settlement (2021).
